MedTrace Logo

Artificial Pancreas in Latin America

NCT02994277 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-09-12

No results posted yet for this study

Summary

The purpose of this study is to use closed-loop systems with the algorithms designed by the University of Virginia and by the Instituto Tecnologico de Buenos Aires (ITBA)/ Universidad Nacional de La Plata (UNLP)/ Universidad Nacional de Quilmes (UNQ) to determine the infusion of insulin in a prolonged period of time in patients with type 1 diabetes mellitus (T1DM).

Conditions

Interventions

DEVICE

1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm

The UVa algorithm is an already established mathematical model that can be programmed in DiAs software to manage glycaemia in T1DM through a subcutaneous insulin pump and a continous glucose monitoring. This algorthm works on a meal announcement basis and will be tested during the first phase of the trial. The ITBA/UNLP algorithm is a new development with safety mechanisms improved and without need of meal anouncement. This algorithm will be tested during the second phase of the trial.

Sponsors & Collaborators

  • Instituto Tecnológico de Buenos Aires

    collaborator OTHER

  • Universidad Nacional de La Plata

    collaborator OTHER

  • Universidad Nacional de Quilmes

    collaborator UNKNOWN

  • University of Virginia

    collaborator OTHER

  • Fundación Nuria/Cellex

    collaborator UNKNOWN

  • Hospital Italiano de Buenos Aires

    lead OTHER

Principal Investigators

  • Waldo H Belloso, MD · Hospital Italiano de Buenos Aires

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-07-06
Completion
2017-07-07

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02994277 on ClinicalTrials.gov